Transgene’s Moment Of Truth Approaches

French biotech Transgene SA has been through a few transformations in its 37-year history, and the past couple of years have been particularly rocky. However, chairman and CEO Philippe Archinard sees light at the end of the tunnel as the new era of combination immunotherapy arrives.

“We have a few scars. It has not been very fun for us these past two years.” Dr. Philippe Archinard, chairman and CEO of Transgene SA, does not deny the company has had its troubles. However, in an interview with Scrip, he outlined why he believes French biotech company’s time may finally be coming.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business